Compare Heron Therapeutics Inc (HRTX) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Warner Music Group Corp — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Warner Music Group Corp trades at $28.72 (market cap $15.12B). The key difference: Warner Music Group Corp is far larger — about 222.3× Heron Therapeutics Inc's market cap, and Warner Music Group Corp pays a 2.77% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Warner Music Group Corp for 96 Days on average.
| HRTX | WMG | |
|---|---|---|
Market Cap | $68.01M | $15.12B |
Volume | 1,891,941 | 2,966,414 |
Sector | Health | Media |
52-Week High | $1.49 | $34.72 |
52-Week Low | $0.27 | $23.65 |
Typical Hold Time | 35 Days | 96 Days |
Enterprise Value | $174.75M | $19.42B |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.36, down 8.15% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish technical setup and institutional confidence contrast with persistent losses and negative cash flow from operations. Investors face upside from potential operational improvements against the risk of continued financial underperformance in the competitive biotech sector.
Warner Music Group (WMG) trades at $28.91, up 2.66% with strong technical momentum and bullish moving average signals. The company reported solid Q2 2026 earnings, beating EPS estimates with $0.38 vs. $0.34 expected, while revenue growth continues with 2026 projections showing $7.3B. Recent AI partnerships with Suno and NetEase Cloud Music highlight strategic positioning in the evolving music industry landscape.
WMG presents a compelling investment case with 66.7% analyst buy ratings and a $39.50 consensus price target representing 36.6% upside. However, risks include recent CFO departure, ongoing AI copyright litigation, and margin pressure from 2025's 5.44% net margin. The stock's premium valuation at 23.12 P/E requires continued execution on streaming growth and AI initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
